Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Tisagenlecleucel in pediatric R/R B-cell ALL

Andre Baruchel • 28 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T Inotuzumab ozogamicin Tisagenlecleucel
B2001X

Andre Baruchel, MD, PhD, of Hôpital Robert Debre, Paris, France, discusses tisagenlecleucel for pediatric/young adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) as evaluated in the B2001X study (NCT03123939) focusing on prior exposure to blinatumomab and inotuzumab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andre Baruchel

The need for alternative development pathways for CAR T-cell products
2:45
The need for alternative development pathways for CAR T-cell products
Andre Baruchel • 16 Feb 2024
The challenges with CAR T-cell therapy for T-ALL and the progress made to overcome these challenges
4:16
The challenges with CAR T-cell therapy for T-ALL and the progress made to overcome these challenges
Andre Baruchel • 16 Feb 2024
CAR-T therapy in ALL: exploring dual-targeting of CD19 & CD22 to overcome resistance
4:06
CAR-T therapy in ALL: exploring dual-targeting of CD19 & CD22 to overcome resistance
Andre Baruchel • 16 Feb 2024
B-cell ALL with IGH-IL3 rearrangement and eosinophilia
7:17
B-cell ALL with IGH-IL3 rearrangement and eosinophilia
Andre Baruchel • 16 Jul 2020

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals